White House considers Section 301 probe of pharmaceutical imports

- U.S. trade rhetoric has widened: officials are reportedly considering using Section 301 authority to target pharmaceutical imports amid broader tariff threats. - The escalation follows President Trump's May 1 proposal that includes a 25% tariff on cars and trucks and signals pharma could be next under Section 301 scrutiny. - EU trade chairs have called the move 'unacceptable' and warned of retaliatory steps if pharma measures proceed. (x.com) (x.com)